ÂÜÀòÂÒÂ×

Steve Oesterle is a venture partner with Cathay Health and the CBC Group. Most recently, Steve has worked on VC and PE investments as a venture partner or advisor with NEA, EQT, and Temasek. Previously, Steve served as Medtronic’s Senior Vice President for Medicine and Technology and was a member of the Medtronic Executive Committee for 14 years. By forging relationships with global technology partners and technical universities, he oversaw long-term internal technology investments while participating in strategic corporate investments in emerging private companies. He also served as a member of the Business Development and Strategy Committee that approved all corporate acquisitions. During his tenure at Medtronic Steve served on more than 20 boards as a director or observer and built a strong and enduring profile for Medtronic in the global venture capital and private equity communities.

Steve currently serves on the public boards of healthcare MNC Baxter (NYSE: BAX), Boston biotech/cell therapy company Sigilon Therapeutics (NASDAQ. SGTX), Shanghai cardiovascular device company Peijia Medical (HKG: 9996) and Paragon 28, a Foot and Ankle orthopedic company (NYSE: FNA). He also serves on PE-backed companies – CeramTec (CPPIB and BC Partners) global leader in medical and industrial ceramic products, and SHL Medical AG (EQT minority), a market leader in auto-injectors for biologics and VC-backed companies Alcyone Therapeutics - targeted gene therapy for CNS. He is also on the advisory board of Alphabet’s healthcare company, Verily.